CU-CPD107 |
| カタログ番号GC25314 |
CU-CPD107は、TLR8アゴニストとssRNAリガンドに対して差異のある活性を示す選択的な二重活性小分子です。 R848が存在する場合、CU-CPD107はTLR8シグナル伝達阻害剤として作用します（IC50 = 13.7μM）。 ssRNAが存在する場合、CU-CPD107は相乗作用を示し、単独ではTLR8シグナル伝達に影響を与えることができません。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2573912-32-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CU-CPD107 is a selective, dual-activity small-molecule which demonstrated differential activity against the TLR8 agonists and ssRNA ligands. In the presence of R848, CU-CPD107 acts as a TLR8 signaling inhibitor (IC50=13.7 μM). In the presence of ssRNA, CU-CPD107 shows synergistic agonist activities, while CU-CPD107 alone is unable to influence TLR8 signaling.
CU-CPD107, a tetrasubstituted imidazole, inhibits R848-induced TLR8 signaling and shows unexpected synergistic agonist activities in the presence of ssRNA, while CU-CPD107 alone is unable to influence TLR8 signaling.[1]
[1] Yang Y, et al. Nat Commun. 2021 Jul 16;12(1):4351.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *